Table 4.
Aβ pathology group 1 vs Aβ pathology group 2 | Aβ pathology group 1 vs Aβ pathology group 3 | Aβ pathology group 2 vs Aβ pathology group 3 | |||||||
---|---|---|---|---|---|---|---|---|---|
P‐value | odds ratio | 95% confidence interval | P‐value | odds ratio | 95% confidence interval | P‐value | odds ratio | 95% confidence interval | |
CAA severity | 0.583 | 0.520 | 0.050–5.376 | 0.016 | 0.060 | 0.006–0.597 | 0.001 | 0.031 | 0.004–0.240 |
CAA stage | 0.535 | 0.543 | 0.079–3.734 | 0.014 | 0.072 | 0.009–0.588 | 0.002 | 0.133 | 0.037–0.481 |
CAA type 1 | 0.452 | 2.812 | 0.190–41.587 | 0.689 | 1.729 | 0.119–25.179 | 0.035 | 4.861 | 1.115–21.183 |
CAA type 2 | 0.249 | 4.385 | 0.355–54.137 | 0.040 | 12.106 | 1.123–130.467 | 0.162 | 2.761 | 0.665–11.452 |
APOE ε4 allele | 0.998 | 2.678 × 10‐9 | ‐ | 0.998 | 1.176 × 10‐8 | ‐ | 0.021 | 0.228 | 0.064–0.804 |
Arterial hypertension | 0.010 | 0.028 | 0.002–0.426 | 0.042 | 0.080 | 0.007–0.918 | 0.160 | 2.898 | 0.657–12.788 |
Diabetes mellitus | 0.282 | 0.272 | 0.025–2.914 | 0.726 | 0.687 | 0.084–5.606 | 0.207 | 2.530 | 0.597–10.713 |
Alcohol abuse | 1.000 | 1.398 | ‐ | 1.000 | 1.172 x 10‐8 | ‐ | 0.998 | 2.279 × 10‐8 | ‐ |
Aβ‐MTL phase | 0.008 | 5.279 | 1.530–18.210 | 0.042 | 2.867 | 1.039–7.907 | 0.134 | 1.841 | 0.829–4.089 |
Braak‐NFT stage | 0.037 | 3.008 | 1.069–8.466 | 0.137 | 2.095 | 0.790–5.555 | 0.131 | 1.436 | 0.897–2.298 |
CERAD score | 0.034 | 3.322 | 1.092–10.103 | 0.433 | 1.517 | 0.535–4.296 | 0.021 | 2.190 | 1.128–4.253 |
Aβ plaque load | 0.048 | 1.328 | 1.002–1.759 | 0.124 | 1.222 | 0.947–1.577 | 0.303 | 1.087 | 0.928–1.273 |
Aβ N3pE plaque load | 0.009 | 2.613 | 1.271–5.374 | 0.057 | 1.816 | 0.982–3.357 | 0.106 | 1.439 | 0.926–2.237 |
Aβ pS8 plaque load | 0.000 | 2.514 × 10 77 | 1.034 × 10 77–6.112 × 10 77 | ‐ | ‐ | ‐ | 0.099 | 2.110 | 0.868–5.128 |
CDR score | 0.000 | 3.733 × 10 10 | 2.096 × 10 10 –6.650 × 10 10 | 0.997 | 6.324 × 10‐13 | ‐ | 0.389 | 1.289 | 0.724–2.296 |
Aβ = amyloid β, APOE = apolipoprotein E, CAA = cerebral amyloid angiopathy, CDR = clinical dementia rating, CERAD = Consortium to Establish a Registry for Alzheimer's disease, MTL = medial temporal lobe, NFT = neurofibrillary tangle; Aβ/Aβ N3pE/Aβ pS8 plaque load,9 Aβ‐MTL phase,27 Braak‐NFT stage,25 CAA severity,29 CAA stage,30 CAA type,31 CDR score,32 CERAD score.26 Bold values represent statistically significant results.